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Pharmacokinetics of mirtazapine and its hydroxylated metabolite in Japanese psychiatric patients treated with mirtazapine Hirosaki University, Japan Abstract Purpose: This study investigated the pharmacokinetics of mirtazapine (MIR) and its hydroxylated metabolite in Japanese psychiatric patients. Patients and Methods: The subjects were 59 Japanese patients treated with racemic MIR. The steady-state plasma concentrations of MIR and N-desmethylmirtazapine (DMIR), 8-hydroxy-MIR (8-OH-MIR) were measured using high performance liquid chromatography. CYP2D6 genotypes were determined by polymerase chain reaction. Three subjects whose plasma levels of MIR and DMIR were below the limit of detection were regarded as non-adherent and excluded. Multiple regression analysis (stepwise method) was performed to analyze the relationship between subject-independent variables (gender, age, smoking status and number of mutated CYP2D6 alleles) and subjectdependent variables such as plasma concentrations of MIR, DMIR, 8-OH-MIR (ng/ml/mg/kg; all corrected for dose and body weight) and 8-OH-MIR/MIR ratio. Results: Multiple regression analysis revealed that smoking (p=0.016) and gender (p=0.041) had a significant impact on plasma concentrations of MIR. The final models were described by the following equations: Plasma concentration of MIR = 86.6 -31.9 ×smoking status (smoking=1, non-smoking=0) -23.0 × gender (male=1, female=0) (R= 0.45, p=0.002, coefficient of determination (R 2 ) =0.20). Smoking status was a significant factor correlated to plasma concentration of 8-OH-MIR (p=0.034). The final model was described by the following equation: Plasma concentration of 8-OH-MIR (corrected for dose and body weight) = 2.41 -1.59×smoking status (smoking=1, non-smoking=0) (R= 0.29, p=0.034, R 2 =0.08). There were no significant factors correlated to in 8-OH-MIR/MIR ratio in the multiple regression analysis. Conclusion: Gender and smoking polymorphism might affect pharmacokinetics of racemic MIR in Japanese patients.
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Cerebral and peripheral Tryptophan / kynurenine pathway in the pathophysiology of stress-induced bio-behavioural abnormalities
Pascal BARONE (1) François Rabelais University, department of neurosciences, Tours, FRANCE
Abstract KYN pathway (KP) is activated by pro-inflammatory cytokines and can produce pro-oxidative metabolites in the brain of depressed patients. Antidepressant treatment reverses oxidative stress in animal models, we can hypothesize that In an animal model of "chronic stress induced depression" in mice, we previously showed that TRP/ KYN pathway activation produced glutamatergic and pro-oxidative metabolites (3-HK), suggesting that chronic stress accelerates glutamatergic excitotoxicity and oxidative stress. We show here that a chronic treatment with the IDO (indole dioxygenase) inhibitor 1-methyl-tryptophan (1MT) or antidepressant fluoxetine were able to reverse TRP/KYN abnormalities caused by chronic stress. These data suggest that TRP/KYN pathway would play a central role in the pathophysiology of stress-induced bio-behavioural abnormalities. Methods: Mice were confronting the unpredictable chronic mild stress (UCMS) procedure and brain KP metabolites were analysed in relevant brain structures and in the periphery, in saline, 1-MT and fluoxetine treated animals. Results: 1-MT and FLX reverse most of UCMS-induced behavioural abnormalities induced by UCMS and reverse various metabolic alterations of the KP (peripherally and centrally). Conclusions: Our results show that inhibition of the KP by 1MT is as effective as fluoxetine as an antidepressant treatment in the UCMS mice. They show that inhibiting KP subsequently reduces the production of pro-oxidative /neurotoxic metabolic substrates in relevant structures. They suggest that KP would play a central role in the link between neuroinflammation and oxidative stress abnormalities in chronic stress induced mood disorders.
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Microglial STAT3 regulates depressive-like behavior by modulating cytokine expression via neuro-glia communication
